Featured Research

from universities, journals, and other organizations

'Two-faced' cells discovered in colon cancer

Date:
December 13, 2012
Source:
Northwestern University
Summary:
A "two-faced" group of cells at work in human colon cancer can either suppress or promote tumor growth. These cells are a subset of T-regulatory (Treg) cells, known to suppress immune responses in healthy people. The discovery of Treg diversity in cancer and its role in control of cancer inflammation may lead to new approaches for therapeutics.

Northwestern Medicine researchers have discovered a "two-faced" group of cells at work in human colon cancer, with opposing functions that can suppress or promote tumor growth. These cells are a subset of T-regulatory (Treg) cells, known to suppress immune responses in healthy individuals

Related Articles


In this previously unknown Treg subset, the presence of the protein RORγt has been shown to differentiate between cancer-protecting and cancer-promoting properties.

The Northwestern team, led by Khashayarsha Khazaie, research associate professor at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, recently reported their findings in the journal Science Translational Medicine.

"The subset of Tregs that expand in human colon cancer is different from the Tregs that abound in healthy individuals in their ability to suppress inflammation," said Khazaie. "Since their discovery, Tregs have been assumed to be harmful in cancer based on the knowledge that they suppress immunity. More recent clinical studies have challenged this notion. Our work shows that Tregs, by suppressing inflammation, are normally very protective in cancer; it is rather their switch to the expression of RORγt that is detrimental."

The Northwestern team's work builds on observations, which demonstrated that the transfer of Tregs from healthy mice to mice with colitis or colitis-induced cancer actually protected the mice from colitis and colitis-induced cancer.

After identifying the abnormal Treg subset in mice with hereditary colon cancer, Khazaie and lead author Nichole Blatner, research assistant professor at Lurie Cancer Center, worked with Mary Mulcahy, MD, associate professor of hematology and oncology, radiology, and organ transplantation, and David Bentrem, MD, Harold L. and Margaret N. Method Research Professor in Surgery, of Northwestern University Feinberg School of Medicine, to look for the same cells in colon cancer patients.

"To our delight, we found the same Treg alterations in cancer patients," said Khazaie.

Of cancers affecting both men and women, colorectal cancer (cancer of the colon and rectum) is the second leading cancer killer in the United States. In 2012, approximately 140,000 Americans were diagnosed with colon or rectal cancer, while more than 50,000 deaths occurred from either cancer, according to the Centers for Disease Control.

"The significance of our discovery became apparent when by inhibiting RORgt in Tregs we were able to protect mice against hereditary colon cancer," Khazaie said.

He notes that several ongoing clinical trials exist based on targeted elimination of all Tregs in cancer patients. However, the discovery of Treg diversity in cancer, and its central role in control of cancer inflammation, may lead to new approaches for therapeutics.

"Tregs are actually very useful in the fight against cancer," he says. "We can do better by targeting RORγt or other molecules that are responsible for the expansion of this Treg subset, instead of indiscriminately eliminating all Tregs. We are very excited about the therapeutic options that targeting specific subsets of Tregs could provide in human solid tumor cancers, and that is our next immediate goal."

Khazaie's team is moving forward with plans to test novel drugs that inhibit RORγt.

This research was made possible by philanthropic support through the Lurie Cancer Center and Steven Rosen, MD, director of the Lurie Cancer Center and the Genevieve E. Teuton Professor of Medicine at the Feinberg School.

In addition to Northwestern University researchers, Khazaie and Blatner collaborated with Fotini Gounari, University of Chicago, and Christophe Benoist, Harvard Medical School, on this discovery.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. R. Blatner, M. F. Mulcahy, K. L. Dennis, D. Scholtens, D. J. Bentrem, J. D. Phillips, S. Ham, B. P. Sandall, M. W. Khan, D. M. Mahvi, A. L. Halverson, S. J. Stryker, A.-M. Boller, A. Singal, R. K. Sneed, B. Sarraj, M. J. Ansari, M. Oft, Y. Iwakura, L. Zhou, A. Bonertz, P. Beckhove, F. Gounari, K. Khazaie. Expression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer. Science Translational Medicine, 2012; 4 (164): 164ra159 DOI: 10.1126/scitranslmed.3004566

Cite This Page:

Northwestern University. "'Two-faced' cells discovered in colon cancer." ScienceDaily. ScienceDaily, 13 December 2012. <www.sciencedaily.com/releases/2012/12/121213142315.htm>.
Northwestern University. (2012, December 13). 'Two-faced' cells discovered in colon cancer. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2012/12/121213142315.htm
Northwestern University. "'Two-faced' cells discovered in colon cancer." ScienceDaily. www.sciencedaily.com/releases/2012/12/121213142315.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com
Obamacare's Strange New Supreme Court Case

Obamacare's Strange New Supreme Court Case

Newsy (Mar. 4, 2015) President Obama&apos;s healthcare law is facing its second Supreme Court challenge, and it hinges on a single sentence. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins